Why Fungal Toenail Treatments Fail

18 November 2026

By Mark Reyneker, BTech (Podiatry), MSc (Palaeontology), Registered Podiatrist, Foot & Gait Specialist | Founder & Clinical Director, Family Podiatry Centre

Published: 18 November 2026 | Last reviewed: 18 November  2026


Diagnosis, infection location and treatment selection in onychomycosis

Persistent nail dystrophy after antifungal treatment can reflect an incorrect initial diagnosis, a treatment poorly matched to the distribution or severity of infection, persistent mechanical nail damage, slow nail outgrowth, or recurrent infection. In distal and lateral subungual onychomycosis, fungal invasion typically begins at the hyponychium or lateral nail margin and extends through the nail bed and undersurface of the plate. Subungual hyperkeratosis, extensive proximal disease and suspected matrix involvement change the rationale for topical monotherapy. This narrative review examines diagnostic sampling, the evidence for topical and oral antifungals and adjunctive debridement, and the distinction between cosmetic improvement and fungal clearance in laser studies. It also outlines a clinical approach to reassessment after apparent treatment failure.

1. How a treatment can fail before it starts

A patient who has already used several antifungal products may have had the same presumptive diagnosis carried forward through each course. In practice, a treatment can be mismatched in two ways. The clinician may overlook a nonfungal cause of the dystrophy, or may correctly recognise onychomycosis while underestimating the extent of infection. In my view, when treatment starts with the product or device a clinic already offers, it is easy to skip over one of those questions. My clinical priority is to address both before offering another course. Published studies support the relevance of diagnostic confirmation and severity-based treatment selection. They do not establish which contributor accounts for the largest share of failures across routine practice.

Repetitive footwear trauma can cause onycholysis and thickening, particularly in toes that repeatedly contact the shoe. Other mimics include psoriasis, lichen planus and other inflammatory nail disorders. A fungal infection can coexist with any of these. Concurrent interdigital scaling, a jagged proximal border of onycholysis or spikes on dermoscopy may support suspicion of fungus, while pressure-related changes elsewhere on the same foot can point towards a concurrent mechanical component. Dermoscopy also helps select a sampling site. Laboratory confirmation is particularly important before systemic treatment and when the diagnosis is in doubt after an unsuccessful course. 

2. Map the disease through the nail unit

The nail plate is the hard keratin structure we see. The nail bed lies beneath it, and the matrix beneath the proximal nail fold produces most of the plate. In distal and lateral subungual onychomycosis, fungi generally enter near the free or lateral edge. Disease can extend proximally along the bed and into the ventral plate, accompanied by onycholysis and subungual hyperkeratosis. A thick nail can therefore represent a combination of altered plate and retained keratin underneath it. With superficial onychomycosis, the surface of the plate is the main site of invasion. Proximal subungual onychomycosis is a distinct presentation that begins proximally. The subungual pattern described here refers to the common distal and lateral form.

Estimate the percentage of the nail involved, identify the most proximal extent of the change, assess subungual thickness, and record how many nails are affected. Disease approaching the lunula or emerging close to the proximal nail fold should prompt assessment for possible matrix involvement. Its location raises suspicion and does not, by itself, establish matrix invasion. A yellow or white longitudinal streak or dense patch can represent a dermatophytoma, a compact mass of fungal elements that may be difficult to treat. These findings have practical consequences. A small distal lesion with preserved proximal growth has a different prognosis with topical treatment from a markedly thickened nail with disease extending towards the matrix.

3. Take the sample from the part of the nail most likely to answer the question

In the distal and lateral subungual pattern, clip back the detached nail as appropriate and obtain subungual material near the proximal margin of the affected area, where viable organisms are more likely to be found than in the distal free edge. Sampling varies with the presentation. In a superficial pattern, scraping the affected surface can be appropriate. Previous antifungal exposure can also influence the yield, especially from culture. When a negative result conflicts with the clinical picture, review the site and adequacy of sampling and consider a repeat specimen or a complementary test before committing to another course.

4. Match the treatment to the distribution of disease

Topical nail formulations. Mild, limited distal or superficial disease without matrix involvement is the most favourable setting. The drug and its vehicle influence delivery through the plate and along accessible parts of the nail unit. Thick plate, retained subungual keratin and extensive proximal disease make reliable delivery harder. A cream formulated to treat tinea pedis serves a different purpose from a topical nail solution. Topical treatment also requires sustained application over many months.

The efinaconazole phase III trials illustrate the difference between an antifungal effect and complete recovery. In selected patients with 20–50% involvement, once-daily efinaconazole for 48 weeks produced mycological cure in 55.2% and 53.4% at week 52. Complete cure rates were 17.8% and 15.2%, compared with 3.3% and 5.5% for vehicle. Complete cure required both a clinically clear target nail and negative microscopy and culture. These figures apply to the enrolled population and should not be extrapolated to severe matrix-involved disease.

Oral antifungals. Systemic therapy reaches the nail unit through the circulation, which avoids reliance on penetration from the outer plate surface. Oral terbinafine is generally the preferred oral option for confirmed dermatophyte toenail infection when medically suitable. A Cochrane review found oral terbinafine and azoles effective compared with placebo and concluded that terbinafine probably achieves better cure rates than azoles overall. The LION trial also favoured continuous terbinafine over the intermittent itraconazole regimens it studied. Extensive involvement, suspected matrix disease and several affected nails strengthen the case for discussing systemic treatment. Prescribing depends on the likely or confirmed pathogen, comorbidities, medication interactions and applicable prescribing guidance, including assessment of liver risk.

Mechanical debridement.
Reducing excess plate thickness and accessible subungual debris can ease pressure symptoms and improve access for a topical nail formulation. A small randomised study comparing debridement alone with debridement plus topical antifungal lacquer found mycological benefit in the combined group. Because the study lacked a topical-only arm, it cannot isolate the incremental benefit of debridement over lacquer alone. In routine care, its role is to support a treatment plan and manage symptoms.

5. Laser studies and the meaning of a clearer nail

Some US Food and Drug Administration device clearances specify a temporary increase in clear nail in people with onychomycosis. The wording identifies the outcome for which the device was cleared. A photograph showing increased clear nail does not establish mycological cure.

A Cochrane review of topical and device-based treatments found low-certainty evidence that there may be little or no difference in mycological cure between 1064-nm Nd:YAG laser and sham or no treatment. Complete cure was not measured in those comparisons. A prospective randomised trial of short-pulsed 1064-nm Nd:YAG laser also found no meaningful evidence of efficacy with the tested protocol. Laser platforms, schedules and accompanying treatments vary, so those results apply most directly to the studied protocols. When interpreting combination studies, check whether the comparator received the same background antifungal treatment and whether the study verified fungal clearance.

6. Distinguish persistent infection from slow growth and recurrence

  • Clinical cure generally means an entirely clear target nail in trials. A growing band of clear nail can indicate early improvement even while the distal nail remains visibly abnormal.
  • Mycological cure generally means negative direct microscopy and fungal culture in trials. The interpretation of a negative clinical sample still depends on its quality and the context.
  • Complete cure usually requires both clinical and mycological cure. A pre-existing injury or chronic shoe pressure can leave residual dystrophy even when tests no longer detect fungus.

Toenails can take up to 18 months to grow out fully. At follow-up, compare standardised photographs and the position of the proximal edge of the abnormal nail. A widening band of clear proximal growth supports improvement. Abnormality advancing towards the base, or persisting without evidence of clear proximal outgrowth, merits reassessment. Review the original diagnosis, application technique or treatment course, and whether the initial extent made the chosen therapy a reasonable fit. Repeat testing when the result would change the next treatment.

If the nail improves and later deteriorates, consider both relapse and reinfection. The difference is often hard to determine clinically. Examine the plantar skin and toe webs for concomitant tinea pedis and address it if present. Review footwear pressure and repeated trauma as contributors to persistent nail damage. Terbinafine-resistant dermatophytes have been documented in selected patients with confirmed infection and prior treatment failure. Data from referral centres establish that resistance occurs, but cannot establish its frequency in a general clinic population.


Clinical implications

Consider two patients with a thickened great toenail. The first has a small distal-lateral lesion, a clear proximal plate and a positive fungal sample. A topical nail formulation may be reasonable, with follow-up planned around visible new growth. The second has a thick plate, extensive subungual debris and abnormality extending close to the proximal fold. Confirm the infection, assess for matrix involvement and consider whether systemic therapy is medically suitable. Debridement may help with pressure symptoms and access to the affected nail. At baseline, document any shoe trauma or other pathology that could continue to affect the appearance after fungal clearance. 

Book An Appointment

Disclaimer: The word "treatment" in this article refers to the care and management of a patient’s health to prevent, cure, or improve a condition. Treatment results vary and do not necessarily indicate a cure. This article is for informational and educational purposes only and does not constitute medical advice.

About the Author

Mark B. Reyneker, BTech (Podiatry), MSc (Palaeontology) is a podiatrist and Founder & Clinical Director of Family Podiatry Centre, with more than 25 years of clinical experience across South Africa, Malaysia and Singapore. His clinical interests include foot and lower-limb pain, gait and biomechanics, sports-related foot conditions, orthotic therapy and footwear.

Alongside his clinical practice, Mark conducts research into human gait and foot biomechanics. His MSc research at the University of the Witwatersrand investigated human propulsion and the structural properties of the metatarsals. He is also the inventor of A Foot Orthotic, an orthotic technology developed through an international patent family.

References

  1. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. Am Fam Physician. 2021. Full text.
    Available article: https://www.aafp.org/afp/2021/1000/p359

  2. Falotico JM, Lipner SR. Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clin Cosmet Investig Dermatol. 2022. PubMed.
    Available article: https://pubmed.ncbi.nlm.nih.gov/36133401/

  3. Piraccini BM, et al. Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project. Dermatol Ther (Heidelb). 2022. PubMed.
    Available article: https://pubmed.ncbi.nlm.nih.gov/35262878/

  4. Nenoff P, et al. S1 Guideline onychomycosis. J Dtsch Dermatol Ges. 2023. PubMed.
    Available article: https://pubmed.ncbi.nlm.nih.gov/37212291/

  5. Foley K, et al. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020. Cochrane review.
    Available article: https://www.cochrane.org/evidence/CD012093_are-topical-and-device-based-treatments-effective-people-fungal-infections-toenails

  6. Elewski BE, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013. PubMed.
    Available article:

  7. Kreijkamp-Kaspers S, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017. PubMed.
    Available article:

  8. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999. PubMed.
    Available article:

  9. Malay DS, et al. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: A randomized, controlled trial. J Foot Ankle Surg. 2009. PubMed.
    Available article:

  10. US Food and Drug Administration. Onycho Laser V. 510(k) K241116. Device clearance and indications for use.
    Available article:

  11. Karsai S, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: Results of a prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2017. PubMed.
    Available article:

  12. Hwang JK, et al. Isolation of Terbinafine-Resistant Trichophyton rubrum from Onychomycosis Patients Who Failed Treatment at an Academic Center in New York, United States. J Fungi (Basel). 2023. PubMed.
    Available article:


Frequently Asked Questions

Treatments typically fail due to an incorrect initial diagnosis, poorly matched treatments for the infection's severity, persistent mechanical nail damage, or simple reinfection.

Conditions like shoe trauma or psoriasis mimic fungal infections, meaning antifungal medications will be entirely ineffective if the true cause isn't confirmed by a lab first.

Yes, mild infections may respond to topical solutions, while extensive infections reaching the deep nail bed or matrix usually require oral systemic therapy.

Topical medications struggle to penetrate thick, hardened nail plates or trapped debris, making reliable delivery of the drug to the infection very difficult.

Oral antifungals travel through the bloodstream directly to the nail unit, completely bypassing the need to penetrate the hard outer nail plate.

Physically thinning the nail plate and clearing debris relieves painful shoe pressure and helps topical antifungal treatments penetrate more effectively.

Yes, a fully cured nail may still look thick or distorted due to chronic shoe pressure, previous injuries, or underlying biomechanical foot issues.

Evidence is limited on whether lasers achieve complete mycological clearance, even if they temporarily improve the nail's clear appearance.

Toenails take up to 18 months to grow out fully, so success is measured by looking for a widening band of clear, healthy growth starting at the cuticle.

A relapse means the original fungus was never fully eliminated, whereas a reinfection occurs when a completely cured nail contracts a brand new fungus.

All rights reserved | Blog